The Times of IndiaHealth
Biosimilar drugs breaking high-cost barrier to cancer immunotherapy
Cheaper biosimilar versions of nivolumab are helping more cancer patients in India access immunotherapy, doctors say. Evidence that lower doses may work for Indian patients could further reduce costs, but uneven drug availability and hospital practices remain barriers.
This card is an AI-assisted summary of reporting published by The Times of India. Read the original report before relying on it for medical, legal, financial, safety, or emergency decisions.